The Australian Health Practitioner Regulation Agency (AHPRA) has finally taken action against 57 medical practitioners over what can only be described as Australia’s prescription mill cannabis industry, a “commercial monster” that transforms doctors into what one practitioner called “glorified cannabis dealers.” Whilst this AHPRA medicinal cannabis crackdown is welcome, it barely scratches the surface of a system built on sentiment rather than science, where profit consistently trumps patient safety.
From Medicine to Prescription Mill
What began as a compassionate response to desperate families seeking relief for children with epilepsy has morphed into what the Dalgarno Institute correctly identifies as a prescription mill operating under healthcare’s thin veneer of legitimacy. The numbers that the AHPRA medicinal cannabis crackdown revealed show a system utterly divorced from proper medical oversight.
AHPRA’s investigation uncovered shocking statistics: some practitioners issued over 10,000 prescriptions in just six months, with one doctor writing 17,000 scripts, essentially one every four minutes of a working day. A single pharmacist dispensed nearly one million cannabis products annually. These aren’t careful medical assessments; they’re the hallmarks of industrial-scale drug distribution masquerading as medicine.
The regulator found consultations lasting mere seconds to minutes, making proper patient assessment impossible. Some companies use nurses without medical training to conduct “consultations,” whilst others employ subscription models that automatically bill patients and deliver cannabis products regardless of medical need or outcomes. As one patient discovered, “Despite never having another appointment, he continued to be billed under a subscription model and more cannabis arrived at his door.”
The AHPRA medicinal cannabis crackdown uncovered disturbing mental health casualties. Doctors prescribed high-THC products to patients with histories of psychosis, leading to hospitalisations, psychotic episodes, and tragically, at least one suicide following inappropriate prescribing by a company called Dispensed.
Limited Evidence, Unlimited Prescribing
Here’s the uncomfortable truth that AHPRA’s new guidelines finally acknowledge: except for childhood epilepsy, muscle spasms associated with multiple sclerosis, cancer treatment, and chemotherapy-induced nausea, there is little evidence to support medicinal cannabis use.
Yet according to Therapeutic Goods Administration data, the primary conditions doctors treat include insomnia, chronic pain, and anxiety, conditions for which robust evidence remains lacking. This disconnect between evidence and practice represents a fundamental failure of medical oversight that the AHPRA medicinal cannabis crackdown has exposed.
The “Vote for Medicine” Deception
The rot began with what the Dalgarno Institute identifies as the “vote for medicine” protocol, a deliberate strategy to bypass rigorous clinical trials in favour of emotional manipulation and political pressure. The Victorian Law Reform Commission’s 2014 consultation was manufactured consent, drawing from a mere 99 submissions whilst systematically marginalising evidence-based research on cannabis harms.
Cannabis advocates freely made unsubstantiated claims such as “Many, many people have been cured – from just about anything and everything”, statements that a decade of disappointing clinical outcomes has now debunked. Meanwhile, the facilitators rigged the process from the start, with observers noting they designed it “to validate changes that were essentially a foregone conclusion.”
AHPRA Chief Executive Justin Untersteiner highlighted concerning business models that “prioritise profits over patient safety.” When companies pay doctors to write prescriptions, then directly sell and ship products to patients, the conflict of interest becomes glaringly obvious. This vertically integrated drug business model operates with such efficiency and legal protection that it would make any street dealer envious.
Dr Claire Noonan’s experience exposes the insidious pressure: “There was a bit of pressure to be, perhaps more of a dealer… it’s more being used for my signature on a script.” When doctors earn money based on prescription volume and companies pressure practitioners to override clinical judgement, it stops being medicine—it’s a sophisticated drug distribution network masquerading as healthcare.
The Mental Health Catastrophe
Perhaps most damning is mounting evidence of mental health disasters that doctors directly link to these prescribing practices, evidence that the AHPRA medicinal cannabis crackdown has brought to light. Emergency departments now see patients with medicinal-cannabis-induced psychosis, particularly those with pre-existing mental health conditions. The industry’s relentless drive toward “Chernobyl-strength” products, some containing up to 98% THC concentration, far exceeds anything therapeutic for most patients.
Rohan Dawson’s experience illustrates the predictable outcomes: receiving 27% THC cannabis that left him feeling like he was “on Pluto” and significantly worsened his anxiety. Professor Ian McGregor’s warnings ring prophetic: “Higher-THC products appear to be more linked to mental health adverse outcomes, precipitation of severe anxiety and paranoia in vulnerable individuals, perhaps schizophrenia and manic attacks.”
The irony is palpable: a system supposedly designed to help patients with anxiety and mental health conditions systematically prescribes substances that worsen those very conditions. This isn’t medical negligence, it’s institutionalised harm masquerading as healthcare.
Why This AHPRA Medicinal Cannabis Crackdown Doesn’t Go Far Enough
Whilst AHPRA’s action against 57 practitioners represents progress, the AHPRA medicinal cannabis crackdown falls short of addressing systemic issues:
Regulatory Failure: The Therapeutic Goods Administration’s capitulation to political pressure represents spectacular failure of oversight. By creating loopholes allowing “unapproved medicines” to bypass safety testing, the TGA abdicated its primary responsibility to protect public health. Despite over 11,420 studies costing $4.877 billion, as the Dalgarno Institute notes, “the very best we can come up with is essentially the same therapeutics that were already available.”
Evidence Standards: The medical community continues prescribing products with limited evidence for anxiety and insomnia, conducting uncontrolled experiments on patients. When Western Australia legalised medicinal cannabis in 2017, not a single doctor would initially prescribe it—a warning sign politicians ignored.
Commercial Exploitation: Companies celebrate reaching “cost parity with illicit products”—a telling admission this was never about medicine but creating legal recreational drug access under medical cover. When prescription cannabis becomes cheaper than street drugs, the medical pretence becomes impossible to maintain.
The Need for Proper Medical Standards
Medical professionals wouldn’t prescribe opioids to every patient requesting them, yet that’s precisely what’s happening with medicinal cannabis. Patient demand isn’t clinical indication, and the medical community must return to evidence-based prescribing practices.
The new AHPRA guidelines that followed the AHPRA medicinal cannabis crackdown require thorough patient assessment, proper documentation, coordination with other healthcare providers, and development of exit strategies when treatment proves ineffective. These shouldn’t be revolutionary concepts, they should be standard medical practice.
A Reckoning Long Overdue
Australia’s medicinal cannabis industry stands as a cautionary tale paralleling the opioid crisis: aggressive marketing of high-potency products, regulatory capture, medical professionals pressured against their better judgement, and systematic downplaying of addiction risks. Yet Australia seems determined to repeat these mistakes despite having the benefit of hindsight.
The AHPRA medicinal cannabis crackdown signals recognition that medicinal cannabis prescribing has veered dangerously off course. However, with another 60 practitioners under investigation and a system that activists built on the “vote for medicine” protocol rather than scientific evidence, regulators need much more comprehensive reform.
The focus must shift from commercial access to clinical appropriateness. This means abandoning the political theatre that created this “commercial monster,” returning to evidence-based medicine, and prioritising patient welfare over industry profits. Real patients have suffered, their mental health deteriorated, anxiety worsened, and a system that prioritises convenience over care has damaged their lives.
Until Australia acknowledges that its prescribed medicinal cannabis programme has become what critics always predicted—a coercive addiction-for-profit enterprise—more patients will suffer the inevitable consequences of prioritising politics over patient safety. The evidence was always there, the warnings were clear, and the outcomes were predictable. What’s inexcusable is that we allowed it to happen anyway.
Source:
Australian Health Practitioner Regulation Agency – Medicinal cannabis prescribing
Leave a Reply